Latest studies

Goldilocks-Inspired Design of Mid-Size Macrocycles for Selective Targeting of Human Melanocortin Receptors.

A medicinal-chemistry study designing and testing 14 new macrocyclic peptide analogues as selective ligands for human melanocortin receptors (MC1R, MC3R, MC4R, MC5R). PT-141 (bremelanotide) appears here only as context, cited alongside setmelanotide as a clinical-success example that motivates the macrocycle approach, not as a compound under study. Researchers reported that two new analogues emerged as potent, selective MC4R antagonists and one as a selective agonist, with structure-activity insights for the class. This is early discovery-stage, in-vitro receptor pharmacology; human data are needed before clinical conclusions can be drawn, and the new molecules are experimental, not PT-141. For readers following PT-141, the value is contextual: it situates bremelanotide within an active, credible drug-design field targeting these receptors for metabolic and inflammatory conditions, and underscores how selectivity between receptor subtypes drives both intended effects and side effects. It reports nothing new about PT-141's own efficacy or safety.